With the 2020 approval of Nivolumab and Ipilimumab for metastatic NSCLC with PDL1 >1%, what is your preferred first line treatment option for a fit patient who is PDL1 positive (1-49%) with no driver mutations?

Topics: Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Indiana University • NCI-CCC Thoracic Tumor Board Question

Answer from: Medical Oncologist at Academic Institution

My preferred first line option for patients with advanced NSCLC and PDL1 TPS score of >1% and <50-% remains chemotherapy with immunotherapy. I prefer carboplatin- pemetrexed -pembrolizumab for nonsquamous and carboplatin-taxane-pembrolizumab for squamous cell NSCLC. I might consider Nivolumab ...

Comments

Medical Oncologist at Yuma Regional Medical Center Cancer Center
I would add that patients who recurred after durva...

Medical Oncologist at University of Michigan Medical School
Agree with @Shadia I. Jalal. I would use chemo-imm...

Related Questions